Defence Therapeutics Inc.
DTC
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.32M | 1.10M | 5.42M | 5.95M | 6.37M |
| Depreciation & Amortization | 73.50K | 77.90K | 70.30K | 66.80K | 31.90K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.16M | 2.34M | 7.65M | 8.86M | 9.29M |
| Operating Income | -2.16M | -2.34M | -7.65M | -8.86M | -9.29M |
| Income Before Tax | -2.67M | -2.99M | -8.53M | -9.72M | -10.10M |
| Income Tax Expenses | -- | -- | -- | -- | -78.20K |
| Earnings from Continuing Operations | -2.67 | -2.99 | -8.53 | -9.72 | -10.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.67M | -2.99M | -8.53M | -9.72M | -10.03M |
| EBIT | -2.16M | -2.34M | -7.65M | -8.86M | -9.29M |
| EBITDA | -2.10M | -2.28M | -7.59M | -8.80M | -9.25M |
| EPS Basic | -0.06 | -0.07 | -0.19 | -0.22 | -0.23 |
| Normalized Basic EPS | -0.04 | -0.04 | -0.12 | -0.14 | -0.14 |
| EPS Diluted | -0.06 | -0.07 | -0.19 | -0.22 | -0.23 |
| Normalized Diluted EPS | -0.04 | -0.04 | -0.12 | -0.14 | -0.14 |
| Average Basic Shares Outstanding | 186.45M | 181.85M | 179.75M | 178.10M | 175.81M |
| Average Diluted Shares Outstanding | 186.45M | 181.85M | 179.75M | 178.10M | 175.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |